GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, commonly known as GSK, is a leading global healthcare company headquartered in India. Established in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK has since made significant strides in the pharmaceutical industry, focusing on research and development across various therapeutic areas, including vaccines, oncology, and respiratory health. With a strong presence in major operational regions such as Europe, North America, and Asia, GSK is renowned for its innovative core products, including vaccines like Shingrix and treatments for chronic diseases. The company’s commitment to scientific excellence and patient-centric solutions has solidified its market position, making it a trusted name in healthcare. GSK continues to achieve notable milestones, driving advancements that enhance global health outcomes.
DitchCarbon Score
How does GlaxoSmithKline Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GlaxoSmithKline Pharmaceuticals Limited's score of 9 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
GlaxoSmithKline Pharmaceuticals Limited's reported carbon emissions
In 2023, GlaxoSmithKline Pharmaceuticals Limited reported total carbon emissions of approximately 10,689,710 kg CO2e, a slight decrease from about 10,994,650 kg CO2e in 2022. The emissions breakdown for 2023 includes approximately 486,950 kg CO2e from Scope 1 and about 10,202,750 kg CO2e from Scope 2 emissions. Despite this reduction, the company has not disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or any formal climate pledges. This indicates a need for further commitment to climate action within the pharmaceutical industry, particularly in setting measurable targets for emissions reduction. Overall, while GSK has made progress in reducing its carbon footprint, the absence of defined reduction strategies highlights an opportunity for enhanced climate commitments moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 286,210 | 000,000 |
| Scope 2 | 10,708,440 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GlaxoSmithKline Pharmaceuticals Limited is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
